Novartis’ cancer drug Afinitor extended progression-free survival (PFS) in a late-stage study of patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, paving the way for an expanded indication. The company said that the Phase III RADIANT-4 study Afinitor (everolimus) tablets plus best supportive care in …